|Designation||Lead Research Scientist|
Dr. Kishore Cholkaris currently working as a Formulation Development Scientist (Project Lead) at Custopharm Inc, Carlsbad, California, USA. His work focuses mainly on development of specialty products for injections and topical application of small and large molecules (biologics). He is an active member of American Association of Pharmaceutical Scientists (AAPS), Association for Research in Vision and Ophthalmology (ARVO), Pharmaceutical Sciences Graduate Student Association (PGSRM), United States Pharmacopeia and Ophthalmology group (OMICS). Dr. Cholkar received the First Best Poster Award from Ophthalmology group in 2014 at the Ophthalmology 2014, Baltimore, USA and Worldwide Outstanding Dissertation Honorable Mention Award in 2016 from UMKC, Missouri, USA. He is the first author of more than 15 scholarly articles in peer-reviewed journals and is credited with more than 560 independent citations on google scholar for his work.
Dr. Kishore Cholkar’s primary interest lies is development of drug delivery systems for small and macromolecules (biologics), achieving a safe and effective delivery of drugs to the site of action in a patient compliance route. Most of Dr. Cholkar’ research focuses on development of biocompatible and biodegradable polymers for drug delivery. Drug delivery to targeted site with the aid of a targeting moiety is another intriguing interest. Experiment results from Dr. Cholkar’s past research suggested that nanomicelles may follow conjunctival-scleral pathway and deliver drugs to back-of-the-eye tissues (retina-choroid). However, there remains a question about the mechanism of drug delivery and drug elimination pathway from posterior ocular tissues. Therefore, Dr. Cholkar’s research plans are: (I) target deliver steroids (dexamethasone and triamcinolone acetonide) and biologics with topical drops to back of the eye tissues; (II) to study the factors (nanomicellar size, shape, surface morphology and ligand density) responsible for effective steroid delivery;(III) to (a) understand and delineate the mechanism of nanomicelle uptake by human conjunctival (hCEC) and human retinal pigment epithelial (ARPE-19/D407) cells (b) understand and determine permeability mechanism for nanomicelles on ocular cell monolayer (hCEC and ARPE-19/D407) and tissues (bovine conjunctiva, sclera, retina-choroid and sclera-choroid-retinal (RCS) tissues) (c) to study the intracellular fate of nanomicelles; (IV) to delineate the pathway accessed by nanomicelles to eliminate drugs from back-of-the-eye tissues in ex vivo and in vivomodels; (V) to study circumvention of efflux transporters by targeted nanomicelles.